Ehab Rasmy Bendas Wasef

01/01/2024

https://nmj.mums.ac.ir/article_23366_451be14da38e76cf3179afef52cbcddd.pdf

Ehab Rasmy Bendas Wasef

09/12/2023

https://www.sciencedirect.com/science/article/abs/pii/S0277538723005053

Ehab Rasmy Bendas Wasef

24/04/2023

https://www.thieme-connect.com/products/ejournals/abstract/10.1055/a-2061-7074

Ehab Rasmy Bendas Wasef

Mohammed Abdallah Ahmed, Nadia M. Morsi

15/11/2022

https://www.tandfonline.com/doi/full/10.1080/10717544.2022.2144546

Ehab Rasmy Bendas Wasef

01/01/2022

https://link.springer.com/content/pdf/10.1186/s43094-022-00400-0.pdf

Ehab Rasmy Bendas Wasef

BA Daihom, MI Mohamed, AA Badawi

01/10/2020

This work aims to develop and evaluate buoyant beads embedded with domperidone/Dowex 50WX2 resinate complex as novel multiple-unit type oral gastro-retentive drug delivery system. Domperidone (BCS II) has been chosen for gastric retention as it has a poor oral bioavailability (around 15%), a short biological half-life, and pH-dependent solubility with poor solubility at a high pH and good solubility at low pH. Two different techniques were used to induce beads buoyancy; first, formulation of effervescent beads by incorporation of NaHCO3 in the beads, which will release carbon dioxide gas upon reaction with the acidic gastric fluid causing the beads to float. Second, is the formation of low-density emulgel beads by the incorporation of light mineral oil in the beads. Resinate complex is used to control the drug release from the prepared formulations. Beads were evaluated for percent drug entrapment efficiency, floating behavior (float lag time and duration), mean particle diameter, in vitro drug release, and release kinetics in SGF. The effect of different concentrations of both NaHCO3 (1%, 2%, and 10%) and light mineral oil (2%, 5%, and 10%) on the floating behavior and physical appearance was studied. The optimized formula (F10) was subjected to a four-week stability study at both 25 °C and 40 °C. Results revealed that gastro-retentive beads possessed a floating duration of up to 24 h and no floating lag time was developed. The novel resinate loaded beads succeeded to sustain the release of domperidone in SGF. The optimized formula was stable at both temperatures of 25 °C and 40 °C for four weeks. Hence, the developed optimized formulation (F10) is considered as a potential to increase the domperidone bioavailability, decrease dosage frequency, and increase patient compliance.

Ehab Rasmy Bendas Wasef

BA Daihom, MI Mohamed, AA Badawi

01/08/2020

Purpose The present work aims to develop and characterize domperidone resinate complex to be loaded into a gastroretentive delivery system. The formed resinate complex will be used to control the drug release in the stomach from inside the gastroretentive delivery system. Methods Resinate complexes were formulated by a simple aqueous binding method. Screening of different types of resins was carried out. Domperidone binding study was tested at various drug and resin concentrations. Physicochemical characterizations were carried out to evaluate the prepared resinate complex. These studies included flow properties, in vitro drug release in simulated gastric fluid (SGF), Differential scanning calorimetry (DSC), Mass spectroscopy and XPRD evaluations. Also, the stability study of the selected resinate complex was conducted at 25 °C and 40 °C for up to one month. Results Domperidone and Dowex 50WX2 in a ratio of 1:3 have formed a resinate complex that has shown acceptable flow properties, thermal properties and short-term chemical stability at 25 °C and 40 °C. Domperidone release profile from resinate in SGF has shown slow controlled release characteristics. Conclusion The domperidone stable complex with Dowex ion exchange resin has the potential for further development as gastroretentive drug delivery system as a mean of controlling the drug release.

Ehab Rasmy Bendas Wasef

Daihom, Baher A., Ehab R. Bendas, Magdy I. Mohamed, and Alia A. Badawi.

01/07/2020

Ehab Rasmy Bendas Wasef

Baher A. Daihom, Magdy I. Mohamed , Alia A. Badawi

01/06/2020

Ehab Rasmy Bendas Wasef

Mamdouh R. Rezk, Kamal A. Badr

01/02/2018

Background and Objectives The purpose of this study was to apply the reference-scaled average bioequivalence (RSABE) approach to evaluate the bioequivalence and to investigate the pharmacokinetic properties of two formulations of fixed dose combination (FDC) tablet of sofosbuvir (SOF) and ledipasvir (LED) (400/90 mg) in 36 healthy Egyptian volunteers. Methods The study was performed in single-dose, randomized-sequence, open-label, reference-replicated, 3-period crossover design (RTR, TRR, RRT), with a washout period of 2 weeks. A rapid and simple LC–MS/MS method was developed and validated for the simultaneous estimation of SOF and LED using eplerenone as an internal standard (IS). Results The results showed that the 90% confidence intervals (CIs) for natural log-transformed ratios of Cmax, AUClast and AUC∞ of SOF (89.95–115.31, 98.77–109.75 and 98.79–109.75) were within the RSABE acceptance limits. The 90% CIs for natural log-transformed ratios of Cmax and AUClast of LED (87.33–115.15 and 83.82–112.26) were within the FDA bioequivalence limits (80.00–125.00). In addition, the in vitro dissolution study was done and both formulations released > 85% of drug within 15 min in the proposed dissolution medium. Conclusions In conclusion, bioequivalence between the two fixed-dose combination products was demonstrated for both active ingredients.

Ehab Rasmy Bendas Wasef

Shaimaa El-Housiny, Dalia Attia, Mohamed A El-Nabarawi

01/02/2017

Abstract: To overcome the disadvantage of the oral routes of antifungal fluconazole, new topical formulation was prepared in the form of solid lipid nanoparticles (SLNs) formulations. The fluconazole-SLNs were manufactured by modified high shear homogenization and ultrasonication method technique in which geleol was used as the solid lipid phase, tween 80, cremophor RH 40 and poloxamer 407 series as the surfactants. The produced fluconazole SLNs were characterized for particle size, zeta potential, entrapment efficiency, morphology by TEM and in-vitro release profiles. Also the optimized fluconazole-SLNs formulation was incorporated into carbopol gel and investigated for in-vitro antifungal activity. The results of the study revealed that fluconazole loaded SLNs showed extremely spherical shape having enriched core drug loading pattern with uniform particle size. A relatively high drug entrapment efficiency ranging from 41.45 to 77.94 % was obtained with zeta potential values lie between -24 to -29.8 mV indicating good stability. DSC examination revealed that fluconazole encapsulated in SLNs was in the amorphous state. In-vitro release study showed a sustained release of fluconazole from the SLNs up to 24 h following Higuchi order equations. In conclusion, SLNs with excellent particle size, high entrapment efficiency and controlled drug release can be produced representing a promising carrier for topical delivery of fluconazole. 1

Ehab Rasmy Bendas Wasef

Mamdouh R Rezk, Emad B Basalious, Iman A Karim

01/09/2016

Ehab Rasmy Bendas Wasef

Mamdouh R Rezk, , Emad B Basalious, Iman A Karim

01/06/2016

A rapid and sensitive LC–MS/MS method was developed, optimized and validated for quantification of sofosbuvir (SF) and ledipasvir (LD) in human plasma using eplerenone as an internal standard (IS). Analytes and IS were extracted from plasma by simple liquid–liquid extraction technique using methyl tertiary butyl ether. The prepared samples were chromatographed on Acquity UPLC BEH C18 column. Separation was done using a mobile phase formed of 0.1% formic acid and acetonitrile (50:50, v/v) in an isocratic mode at a flow rate of 0.4 ml/min. The Xevo TQD LC–MS/MS was operated under the multiple-reaction monitoring mode using electrospray ionization. A full validation of the method was performed according to the FDA guidelines. Linearity was found to be in the range of 0.25–3500 ng/ml for SF and 5–2000 ng/ml for LD. The intra-day and inter-day precision and accuracy results were within the acceptable limits. A short run time of 2 min allows analysis of more than 400 plasma samples per day. The developed method was successfully applied to both fasting and fed bioequivalence studies in healthy human volunteers.

Ehab Rasmy Bendas Wasef

Lamyaa Bazan, Omaima N El Gazayerly, Sabry Sayed Badawy

01/05/2016

In order to target celecoxib which is a COX2 inhibitor, with potentials in the prevention and treatment of colitis and colon cancer, it was formulated as microparticles using the solvent/evaporation method and various pH-dependent Eudragit polymers. The in-vitro evaluation of the prepared microparticles showed spherical and smooth morphology. The encapsulation efficiency and yield were high, indicating that the method used is simple and efficient at this scale. The in-vitro release study showed no release in the acidic medium for 2 h followed by the release of the drug in pH 6.8 in case of Eudragit L100-55 and L100 and pH 7.4 in case of Eudragit S100. The pharmacokinetic parameters were calculated and method validation was performed to insure that it is suitable and reliable. Pharmacokinetic parameters were investigated by determining the Cmax, Tmax, AUC0–t, Kel, and t1/2 of the drug as a suspension and as microparticles. There was a significant difference (p < 0.05) in Tmax between the drug as a suspension and as microparticles. The effect of celecoxib on the degree of inflammation was examined on acetic acid induced colitis rat model and the drug was given as a suspension and as microparticles. The evaluation was done using macroscopical, microscopical and biochemical examination. There was a significant difference between the acetic acid control group and the treatment groups regarding all examination criteria in the order microparticles formulated using Eudragit S100 followed by Eudragit L100-55 while microparticles using Eudragit L100 and drug suspension showed almost the same results.

Ehab Rasmy Bendas Wasef

Radwa MA Abd-Elal, Rehab N Shamma, Hassan M Rashed

01/04/2016

Migraine attack is a troublesome physiological condition associated with throbbing, intense headache, in one half of the head. Zolmitriptan is a potent second-generation triptan, prescribed for patients with migraine attacks, with or without an aura, and cluster headaches. The absolute bioavailability of zolmitriptan is about 40% for oral administration; due to hepatic first metabolism. Nasal administration would circumvent the pre-systemic metabolism thus increasing the bioavailability of zolmitriptan. In addition, due to the presence of microvilli and high vasculature, the absorption is expected to be faster compared to oral route. However, the bioavailability of nasal administered drugs is particularly restricted by poor membrane penetration. Thus, the aim of this work is to explore the potential of novel nanovesicular fatty acid enriched structures (novasomes) for effective and enhanced nasal delivery of zolmitriptan and investigate their nose to brain targeting potential. Novasomes were prepared using nonionic surfactant, cholesterol in addition to a free fatty acid. A 23 full factorial design was adopted to study the influence of the type of surfactant, type of free fatty acid and ratio between the free fatty acid and the surfactant on novasomes properties. The particle size, entrapment efficiency, polydispersity index, zeta potential and % zolmitriptan released after 2 h were selected as dependent variables. Novasomes were further optimized using Design Expert® software (version 7; Stat-Ease Inc., Minneapolis, MN), and an optimized formulation composed of Span® 80:Cholesterol:stearic acid (in the ratio 1:1:1) was selected. This formulation showed zolmitriptan entrapment of 92.94%, particle size of 149.9 nm, zeta potential of −55.57 mV, and released 48.43% zolmitriptan after 2 h. The optimized formulation was further examined using transmission electron microscope, which revealed non-aggregating multi-lamellar nanovesicles with narrow size distribution. DSC, XRD examination of the optimized formulation confirmed that the drug have been homogeneously dispersed throughout the novasomes in an amorphous state. In-vivo bio-distribution studies of 99mTc radio-labeled intranasal zolmitriptan loaded novasomes were done on mice, the pharmacokinetic parameters were compared with those following administration of intravenous 99mTc-zolmitriptan solution. Results revealed the great enhancement in zolmitriptan targeting to the brain, with drug targeting potential of about 99% following intranasal administration of novasomes compared with the intravenous drug solution. Zolmitriptan loaded novasomes administered via the nasal route may therefore constitute an advance in the management of acute migraine attacks.

Ehab Rasmy Bendas Wasef

and Ossama S Neaz Eglal R Souaya , Mostafa M H Khalil, Eman H Ismail

01/01/2014

Ehab Rasmy Bendas Wasef

Saly Sherif, Sabry Badawy

01/01/2013

Cubosomes are discrete, sub-micron, nanostructured particles of the bicontinuous cubic liquid crystalline phase. Such novel particles are utilized to encapsulate guest molecules which are either hydrophilic, lipophilic or amphiphilic, due to the compartmentalization of its structure. Cubosomes usually have been produced by means of time-consuming methods involving high energy input “Top-down approach”. However, the application of high energy is regarded as a barrier to temperature sensitive ingredients and is difficult to scale up. As a result, it was useful to develop a process for producing cubosomes that requires no significant energy input as the “Bottom-up approach”. The purpose of this study was to evaluate the efficiency of both approaches in fabrication of cubosomes. Dispersions were characterized by visual inspection, optical and transmission electron microscopy, encapsulation efficiency and in-vitro release. Results indicated that the bottom-up approach using less energy input was more efficient in generation of smaller cubosomes with higher encapsulation efficiency and slower release rate